258 related articles for article (PubMed ID: 22284696)
21. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
Luo J; Jensen DE; Maroni BJ; Brunelli SM
Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
[TBL] [Abstract][Full Text] [Related]
22. The Predictive Value of Platelet/Lymphocyte Ratio in Hemodialysis Patients With Erythropoietin Resistance.
Taymez DG; Ucar E; Turkmen K; Ucar R; Afsar B; Gaipov A; Turk S
Ther Apher Dial; 2016 Apr; 20(2):118-21. PubMed ID: 26929254
[TBL] [Abstract][Full Text] [Related]
23. Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study.
Hara A; Koshino Y; Kurokawa Y; Shinozaki Y; Miyake T; Kitajima S; Toyama T; Iwata Y; Sakai N; Shimizu M; Furuichi K; Nakamura H; Wada T
Clin Exp Nephrol; 2020 Jan; 24(1):88-95. PubMed ID: 31502102
[TBL] [Abstract][Full Text] [Related]
24. Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol.
Afsar B; Agca E; Turk S
J Clin Pharmacol; 2015 Nov; 55(11):1280-5. PubMed ID: 26032009
[TBL] [Abstract][Full Text] [Related]
25. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
Malovrh M; Hojs N; Premru V
Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
[TBL] [Abstract][Full Text] [Related]
26. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
[TBL] [Abstract][Full Text] [Related]
27. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Pergola PE; Devalaraja M; Fishbane S; Chonchol M; Mathur VS; Smith MT; Lo L; Herzog K; Kakkar R; Davidson MH
J Am Soc Nephrol; 2021 Jan; 32(1):211-222. PubMed ID: 33272965
[TBL] [Abstract][Full Text] [Related]
28. Renal anemia treatment with ESA in hemodialysis patients in relation to early versus late referral in everyday clinical practice in Central and Eastern European countries: baseline data.
Malyszko J; Drozdz M; Zolkiewicz A; Rutkowski B
Kidney Blood Press Res; 2012; 35(1):58-67. PubMed ID: 21876362
[TBL] [Abstract][Full Text] [Related]
29. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
30. Changing patterns of anemia management in US hemodialysis patients.
Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
[TBL] [Abstract][Full Text] [Related]
31. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
[TBL] [Abstract][Full Text] [Related]
32. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
[TBL] [Abstract][Full Text] [Related]
33. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
34. Hepcidin for clinicians.
Young B; Zaritsky J
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1384-7. PubMed ID: 19556376
[TBL] [Abstract][Full Text] [Related]
35. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
[No Abstract] [Full Text] [Related]
36. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
[TBL] [Abstract][Full Text] [Related]
37. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
Chiang CK; Yang SY; Peng YS; Hsu SP; Pai MF; Huang JW; Hung KY; Wu KD
Am J Nephrol; 2009; 29(5):392-7. PubMed ID: 18974640
[TBL] [Abstract][Full Text] [Related]
38. Credibility of the measurement of serum ferritin and transferrin receptor as indicators of iron deficiency anemia in hemodialysis patients.
Mahdavi MR; Makhlough A; Kosaryan M; Roshan P
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1158-62. PubMed ID: 22165676
[TBL] [Abstract][Full Text] [Related]
39. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
40. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study.
Tanaka S; Kitamura H; Tsuruya K; Kitazono T; Nakano T;
Clin Exp Nephrol; 2022 Sep; 26(9):867-879. PubMed ID: 35507237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
